Login / Signup
Optimality, Future and Terminal Costs: Comment on "Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran".
Noga Gershon
Yakir Berchenko
Published in:
PharmacoEconomics (2019)
Keyphrases
</>
positive breast cancer
early stage
epidermal growth factor receptor
current status